Supernus Pharmaceuticals (SUPN) Given “Buy” Rating at B. Riley

B. Riley restated their buy rating on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a report issued on Thursday. The firm currently has a $54.00 price target on the specialty pharmaceutical company’s stock.

SUPN has been the topic of several other research reports. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, January 12th. Piper Jaffray Companies restated a hold rating and set a $41.00 price target on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 26th. Cantor Fitzgerald restated a buy rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. FBR & Co started coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a buy rating and a $53.00 price target on the stock. Finally, SunTrust Banks restated a buy rating and set a $61.00 price target on shares of Supernus Pharmaceuticals in a research note on Friday, November 3rd. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $49.90.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) traded up $3.35 on Thursday, hitting $46.90. 1,233,736 shares of the stock traded hands, compared to its average volume of 528,698. Supernus Pharmaceuticals has a 52 week low of $23.10 and a 52 week high of $50.04. The firm has a market cap of $2,590.00, a price-to-earnings ratio of 42.64 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The business’s revenue for the quarter was up 41.5% on a year-over-year basis. equities research analysts forecast that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.

In related news, VP Victor Vaughn sold 5,750 shares of the firm’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $45.03, for a total value of $258,922.50. Following the transaction, the vice president now directly owns 15,094 shares in the company, valued at approximately $679,682.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the firm’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $44.98, for a total transaction of $899,600.00. Following the completion of the transaction, the vice president now owns 32,500 shares in the company, valued at $1,461,850. The disclosure for this sale can be found here. Insiders sold a total of 145,750 shares of company stock worth $6,173,173 over the last quarter. 6.70% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of SUPN. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Supernus Pharmaceuticals by 278.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares during the last quarter. Riverhead Capital Management LLC grew its stake in Supernus Pharmaceuticals by 91.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,462 shares during the last quarter. Advisor Group Inc. grew its stake in Supernus Pharmaceuticals by 13.7% in the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after buying an additional 410 shares during the last quarter. Victory Capital Management Inc. grew its stake in Supernus Pharmaceuticals by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 517 shares during the last quarter. Finally, Flinton Capital Management LLC grew its stake in Supernus Pharmaceuticals by 88.9% in the 2nd quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock valued at $205,000 after buying an additional 2,240 shares during the last quarter. Institutional investors and hedge funds own 98.22% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Supernus Pharmaceuticals (SUPN) Given “Buy” Rating at B. Riley” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://stocknewstimes.com/2018/01/20/supernus-pharmaceuticals-supn-given-buy-rating-at-b-riley.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply